Skip to main content

Advertisement

SpringerLink
Log in

Dermatofibrosarcoma Protuberans: an Update and Review

  • Skin Cancer (JA Carucci, Section Editor)
  • Published:
Current Dermatology Reports Aims and scope Submit manuscript

Abstract

Dermatofibrosarcoma protuberans (DFSP) is a rare, infiltrative, spindle cell tumor with a propensity for deep invasion. Definitive treatment is with surgical excision, either Mohs micrographic surgery (MMS) or wide local excision (WLE). Metastasis is rare, but local recurrence is common. Imatinib mesylate is approved for the treatment of unresectable DFSP, recurrent DFSP that cannot be re-resected, and metastatic DFSP. Radiation therapy is sometimes used to treat unresectable DFSP or as an adjuvant treatment modality after surgical excision. MRI is not routinely used but is a useful imaging tool in atypical, recurrent, or difficult cases to better delineate tumor depth or involvement of critical structures. Close clinical follow-up is recommended every 6 to 12 months after treatment given the high rates of local recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Criscione VD, Weinstock MA. Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. J Am Acad Dermatol. 2007;56:968–73.

    Article  PubMed  Google Scholar 

  2. Sachdev R, Sundram U. Expression of CD163 in dermatofibroma, cellular fibrous histiocytoma, and dermatofibromasarcoma protuberans: comparison with CD68, CD34, and factor XIIIa. J Cutan Pathol. 2006;33:353–60.

    Article  PubMed  Google Scholar 

  3. Dubay D, Cimmino V, Lowe L, Johnson TM, Sondak VK. Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. Cancer. 2004;100:1008–16.

    Article  PubMed  Google Scholar 

  4. Bowne WB, Antonescu CR, Leung DH, Katz SC, Hawkins WG, Woodruff JM, et al. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer. 2000;88:2711–20.

    Article  CAS  PubMed  Google Scholar 

  5. Farma JM, Ammori JB, Zager JS, Marzban SS, Bui MM, Bichakjian CK, et al. Dermatofibrosarcoma protuberans: how wide should we resect? Ann Surg Oncol. 2010;17:2112–8.

  6. Roh MR, Bae B, Chung KY. Mohs micrographic surgery for dermatofibrosarcoma protuberans. Clin Exp Dermatol. 2010;35(8):849–52.

    Article  CAS  PubMed  Google Scholar 

  7. Paradisi A, Abeni D, Rusciani A, Cigna E, Wolter M, Scuderi N, et al. Dermatofibrosarcoma protuberans: wide local excision vs. Mohs micrographic surgery. Cancer Treat Rev. 2008;34:728–36.

    Article  CAS  PubMed  Google Scholar 

  8. Johnson-Jahangir H, Sherman W, Ratner D. Using imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: potential pluses and minuses. J Natl Compr Cancer Netw. 2010;8:881–5.

    CAS  Google Scholar 

  9. Monnier D, Vidal C, Martin L, Danzon A, Pelletier F, et al. Dermatofibrosarcoma protuberans: a population-based cancer registry descriptive study of 66 consecutive cases diagnosed between 1982 and 2002. J Eur Acad Dermatol Venereol. 2006;20(10):1237–42.

    Article  CAS  PubMed  Google Scholar 

  10. Bichakijan CD, Olencki T, Alam M, Andersen JS, Berg D, Bowen GM, et al. Dermatofibrosarcoma protuberans, version 1.2014. J Natl Compr Cancer Netw. 2014;12:863–8. An excellent review of the current guidelines for the treatment of DFSP.

    Google Scholar 

  11. Morman MR, Lin RY, Petrozzi JW. Dermatofibrosarcoma protuberans arising in a site multiple immunizations. Arch Dermatol. 1979;115:1453.

    Article  CAS  PubMed  Google Scholar 

  12. McLelland J, Chu T. Dermatofibrosarcoma protuberans arising in a BCG vaccination scar. Arch Dermatol. 1988;124:496–7.

    Article  CAS  PubMed  Google Scholar 

  13. Seo JK, Cho KJ, Kang JH, Lee D, Sung HS, Hwang SW. Dermatofibrosarcoma protuberans arising from a burn scar. Ann Dermatol. 2009;21:416–8.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Tanaka A, Hatoko M, Tada H, Kuwahara M, Iioka H, Niitsuma K. Dermatofibrosarcoma protuberans arising from a burn scar in the axilla. Ann Plast Surg. 2004;52:423–5.

    Article  PubMed  Google Scholar 

  15. Zaiden R, Latif N, Pham D, Hosenpud J. Dermatofibroma protuberans arising from an infected insect bite. Clin Adv Hematol Oncol. 2009;7:404–8.

    PubMed  Google Scholar 

  16. Diaz-Cascajo C, Bastida-Inarrea J, Borrego L, Carretero-Hernandez G. Comparison of p53 expression in dermatofibrosarcoma protuberans and dermatofibroma: lack of correlation with proliferation rate. J Cutan Pathol. 1995;22:304–9.

    Article  CAS  PubMed  Google Scholar 

  17. Hisaoka M, Okamoto S, Morimitsu Y, Tsuji S, Hashimoto H. Dermatofibrosarcoma protuberans with fibrosarcomatous areas. Molecular abnormalities of the p53 pathway in fibrosarcomatous transformation of dermatofibrosarcoma protuberans. Virchows Arch. 1998;433:323–9.

    Article  CAS  PubMed  Google Scholar 

  18. Takahira T, Oda Y, Tamiya S, Yamamoto H, Kawaguchi K, Kobayashi C, et al. Microsatelite instability and p53 mutation associated with tumor progression in dermatofibromasarcoma protuberans. Hum Pathol. 2004;35:240–5.

    Article  CAS  PubMed  Google Scholar 

  19. Patel KU, Szabo SS, Hernandez VS, Prieto VG, Abruzzo LV, Lazar AJ, et al. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcriptase polymerase chain reaction and fluorescence in situ hybridization assays. Hum Pathol. 2008;39:184–93.

    Article  CAS  PubMed  Google Scholar 

  20. Pedeutour F, Simon MP, Minoletti F, Sozzi G, Pierotti MA, Hecht F, et al. Ring 22 chromosomes in dermatofibrosarcoma protuberans are low-level amplifiers of chromosomes 17 and 22 sequences. Cancer Res. 1995;55:2400–3.

    CAS  PubMed  Google Scholar 

  21. Llombart B, Sanmartin O, Lopez-Guerrero JA, Monteagudo C, Serra C, Requena C, et al. Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1-PDGFB) study with therapeutic implications. Histopathology. 2009;54:860–72.

    Article  PubMed  Google Scholar 

  22. Simon MP, Pedeutour F, Sirvent N, Grosgeorge J, Minoletti F, Coindre JM, et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet. 1997;15:95–8.

    Article  CAS  PubMed  Google Scholar 

  23. O’Brien KP, Seroussi E, Dal CP, Sciot R, Mandahl N, Fletcher JA, et al. Various regions within the alpha-helical domain of the COL1A1 gene are fused to the second exon of the PDGFB gene in dermatofibrosarcomas and giant-cell fibroblastomas. Gene Chromosome Cancer. 1998;23:187–93.

    Article  Google Scholar 

  24. Shimizu A, O’Brien KP, Sjoblom T, Pietras K, Buchdunger E, Collins VP, et al. The dermatofibrosaroma protuberans associated collagen type I alpha /platelet derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. 1999;59:3719–23.

    CAS  PubMed  Google Scholar 

  25. Duffaud F, Le CA. Imatinib in the treatment of solid tumours. Target Oncol. 2009;4:45–56.

    Article  PubMed  Google Scholar 

  26. Pedeutour F, Coindre JM, Nicolo G, Bouchot C, Ayraud N, Carel CT. Ring chromosomes in dermatofibrosarcoma protuberans contain chromosome 17 sequences: fluorescence in situ hybridization. Cancer Genet Cytogenet. 1993;67:149.

    Article  CAS  PubMed  Google Scholar 

  27. Iwasaki H, Ohjimi Y, Ishiguro M, Isayama T, Fujita C, Kaneko Y, et al. Supernumerary ring chromosomes and nuclear blebs in some low-grade malignant soft tissue tumours: atypical lipomatous tumours and dermatofibrosarcoma protuberans. Virchows Arch. 1998;432:521–8.

    Article  CAS  PubMed  Google Scholar 

  28. Wang J, Hisaoka M, Shimajiri S, Morimitsu Y, Hashimoto H. Detection of COL1A1-PDGFB fusion transcripts in dermatofibrosarcoma protuberans by reverse transcription-polymerase chain reaction using archival formalin-fixed paraffin embedded tissues. Diagn Mol Pathol. 1999;8:113–9.

    Article  CAS  PubMed  Google Scholar 

  29. Takahira T, Oda Y, Tamiya S, Higaki K, Yamamoto H, Kobayashi C, et al. Detection of COL1A1-PDGFB fusion transcripts and PDGFB/PDGFRB mRNA expression in dermatofibrosarcoma protuberans. Mod Pathol. 2007;20:668–75.

    Article  CAS  PubMed  Google Scholar 

  30. Muchemwa FC, Wakasugi S, Honda Y, Ihn H. PDGFB quantification is a useful tool in the diagnosis of dermatofibrosarcoma protuberans: a study of 10 cases. Clin Exp Dermatol. 2010;35:295–9.

    Article  CAS  PubMed  Google Scholar 

  31. Fiore M, Miceli R, Mussi C, Lo VS, Mariani L, Lozza L, et al. Dermatofibrosarcoma protuberans treated a single institution: a surgical disease with a high cure rate. J Clin Oncol. 2005;23:7669–75.

    Article  PubMed  Google Scholar 

  32. Love WE, Keiler SA, Tamburro JE, Honda K, Gosain AK, Bordeaux JS. Surgical management of congenital dermatofibrosarcoma protuberans. J Am Acad Dermatol. 2009;61:1014–23.

    Article  PubMed  Google Scholar 

  33. Martin L, Piette F, Blanc P, Mortier L, Avril MF, Delaunay MM, et al. Clinical variants of the preprotuberant stage of dermatofibrosarcoma protuberans. Br J Dermatol. 2009;153:932–6.

    Article  Google Scholar 

  34. Gershtenson PC, Krunic AL, Chen HM. Multiple clustered dermatofibroma: case report and review of the literature. J Cutan Pathol. 2010;37:e42–5.

    Article  PubMed  Google Scholar 

  35. Marcus JR, Few JW, Senger C, Reynolds M. Dermatofibrosarcoma protuberans and the Bednar tumor: treatment in the pediatric population. J Pediatr Surg. 1998;33:1811–4.

    Article  CAS  PubMed  Google Scholar 

  36. Checketts SR, Hamilton TK, Baughman RD. Congenital and childhood dermatofibrosarcoma protuberans: a case report and review of the literature. J Am Acad Dermatol. 2000;42:907–13.

    Article  CAS  PubMed  Google Scholar 

  37. Reddy C, Hayward P, Thompson P, Kan A. Dermatofibrosarcoma protuberans in children. J Plast Reconstr Aesthet Surg. 2009;62:819–23.

    Article  PubMed  Google Scholar 

  38. Terrier-Lacombe MJ, Guillou L, Maire G, Terrier P, de Vince DR, Saint Aubain SN, et al. Dermatofibrosarcoma protuberans, giant cell fibroblastoma, and hybrid lesions in children: clinicopathologic comparative analysis of 28 cases with molecular data- a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol. 2003;27:27–39.

    Article  PubMed  Google Scholar 

  39. Shmookler BM, Enzinger FM, Weiss SW. Giant cell fibroblastoma. A juvenile form of dermatofibrosarcoma protuberans. Cancer. 1989;64:2154–61.

    Article  CAS  PubMed  Google Scholar 

  40. Gloster Jr HM. Dermatofibrosarcoma protuberans. J Am Acad Dermatol. 1996;35:355–74.

    Article  PubMed  Google Scholar 

  41. Bague S, Folpe AL. Dermatofibrosarcoma protuberans presenting as a subcutaneous mass: a clinicopathologic study of 15 cases with exclusive or near-exclusive subcutaneous involvement. Am J Dermatopathol. 2008;30:327–32.

    Article  PubMed  Google Scholar 

  42. Wood L, Fountaine TJ, Rosamilia L, Helm KF, Clarke LE. Cutaneous Cd34 + spindle cells neoplasms: histopathologic features distinguish spindle cell lipoma solitary fibrous tumor, and dermatofibrosarcoma protuberans. Am J Dermatopathol. 2010;32(80):764–8.

    Article  PubMed  Google Scholar 

  43. Taylor HB, Helwig EB. Dermatofibrosarcoma protuberans. A study of 115 cases. Cancer. 1962;15:717–25.

    Article  CAS  PubMed  Google Scholar 

  44. Pouryazdanparast P, Yu L, Cutlan JE, Olsen SH, Fullen DR, Ma L. Diagnostic value of CD163 in cutaneous spindle cell lesions. J Cutan Pathol. 2009;36:859–64.

    Article  PubMed  Google Scholar 

  45. Mori T, Misago N, Yamamoto O, Toda S, Narisawa Y. Expression of nestin in dermatofibrosarcoma protuberans in comparison to dermatofibroma. J Dermatol. 2008;35:419–25.

    Article  PubMed  Google Scholar 

  46. Sellheyer K, Nelson P, Krahl D. Deramtofibrosarcoma protuberans: a tumour of nestin-positive cutaneous mesenchymal stem c ells? Br J Dermatol. 2009;161:1317–22.

    Article  CAS  PubMed  Google Scholar 

  47. Liang C, Jambusaria-Pahlajani A, Karia P, et al. A systemic review of outcome data for dermatofibrosarcoma protuberans with and without fibrosarcomatous change. J Am Acad Dermatol. 2014;71:781–5. A good article that demonstrates FS-DFSP is higher risk than DFSP.

    Article  PubMed  Google Scholar 

  48. Goldblum JR, Reith JD, Weiss SW. Sarcomas arising in dermatofibrosarcoma protuberans: a reappraisal of biologic behavior in eighteen cases treated by wide local excision with extended clinical follow-up. Am J Pathol. 2000;24:1125–30.

    Article  CAS  Google Scholar 

  49. Mentzel T, Beham A, Katenkamp D, Dei Tos AP, Fletcher CD. Fibrosarcomatous (“high-grade”) dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol. 1998;22:576–87.

    Article  CAS  PubMed  Google Scholar 

  50. Abbot JJ, Oliveira AM, Nascimento AG. The prognostic significance of fibrosarcomatous transformation in dermatofibrosarcoma protuberans. Am J Surg Pathol. 2006;30:436–43.

    Article  Google Scholar 

  51. Goldblum JR. CD34 positivity in fibrosarcomas which arise in dermatofibrosarcoma protuberans. Arch Pathol Lab Med. 1995;119:238–41.

    CAS  PubMed  Google Scholar 

  52. Minter RM, Reith JD, Hochwald SN. Metastatic potential of dermatofibrosaroma protuberans with fibrosarcomatous change. J Surg Oncol. 2003;82:201–8.

    Article  PubMed  Google Scholar 

  53. Kovarik CL, Hsu MY, Cockerell CJ. Neurofibromatous changes in dermatofibrosarcoma protuberans: a potential pitfall in the diagnosis of a serious cutaneous soft tissue neoplasm. J Cutan Pathol. 2004;31:492–6.

    Article  PubMed  Google Scholar 

  54. Nelsen GP, Rosenberg AE, Koerner FC, Young RH, Scully RE. Smooth-muscle tumors of the vulva. A clinicopathologic al study of 25 cases and review of the literature. Am J Surg Pathol. 1996;20:779–93.

    Article  Google Scholar 

  55. Bahrami A, Folpe AL. Adult-type fibrosarcoma: a reevaluation of 163 putative cases diagnosed at a single institution over a 48 years period. Am J Surg Pathol. 2010;34:1504–13.

    Article  PubMed  Google Scholar 

  56. Edelweiss M, Malpica A. Dermatofibrosarcoma protuberans of the vulva: a clinicopathologic and immunohistochemical study of 13 cases. Am J Surg Pathol. 2010;34:393–400.

    Article  PubMed  Google Scholar 

  57. Hoang MP, Selim MA, Bentley RC, Burchette JL, Shea CR. CD34 expression in desmoplastic melanoma. J Cutan Pathol. 2001;28:508–12.

    Article  CAS  PubMed  Google Scholar 

  58. Popov P, Bohling T, Asko-Seljavaara S, Tukiainen E. Microscopic margins and results of surgery for dermatofibrosarcoma protuberans. Plast Reconstr Surg. 2007;119:1779–84.

    Article  CAS  PubMed  Google Scholar 

  59. Chang CK, Jacobs IA, Salti G. Outcomes of surgery for dermatofibrosarcoma protuberans. Eur J Surg Oncol. 2004;30:341–5.

    Article  CAS  PubMed  Google Scholar 

  60. Loss L, Zeitouni NC. Management of scalp dermatofibrosarcoma protuberans. Dermatol Surg. 2005;31:1428–33.

    CAS  PubMed  Google Scholar 

  61. Kasper B, Lossignol D, Gil T, Flamen P, De Saint AN, Awada A. Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp. Anti Cancer Drugs. 2006;17:1223–5.

    Article  CAS  PubMed  Google Scholar 

  62. Marks LB, Suit HD, Rosenberg AE, Wood WC. Deramatofibrosarcoma protuberans treated with radiation therapy. Int J Radiat Oncol Biol Phys. 1989;17:379–84.

    Article  CAS  PubMed  Google Scholar 

  63. Foroozan S, Sei JF, et al. Efficacy of Mohs micrographic surgery in the treatment of dermatofibrosarcoma protuberans: a systemic review. Arch Dermatol. 2012;148:1055–63. An excellent summary of the evidence behind Mohs micrographic surgery for the treatment of DFSP.

    Article  PubMed  Google Scholar 

  64. Llombart B, Serra-Guillen C, Monteagudo C, López Guerrero JA, Sanmartín O. Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management. Semin Diagn Pathol. 2013;30:13–28. A good review of the diagnosis and management of DFSP.

  65. Buck D, Kim J, Alam M, Vinay R, Johnson S, Connor CM, et al. Multidisciplinary approach to the management of dermatofibrosarcoma protuberans. J Am Acad Dermatol. 2012;67:861–6. An excellent article that demonstrates the efficacy of a multidisciplinary approach in the management of DFSP.

  66. Heuvel ST, Suurmeijer A, Pras E, Van Ginkel RJ, Hoekstra HJ. Dermatofibrosarcoma protuberans: recurrence is related to the adequacy of surgical margins. Eur J Surg Oncol. 2010;36:89–94.

    Article  PubMed  Google Scholar 

  67. Matin RN, Acland KM, Williams HC. Is Mohs micrographic surgery more effective than wide local excision for treatment of dermatofibrosarcoma protuberans in reducing risk of local recurrence? A critically appraised topic. Br J Dermatol. 2012;167:6–9. An excellent article that uses the current evidence base to compare the recurrence rates between MMS and WLE in the treatment of DFSP.

  68. Serra-Guillen C, Llombart B, Nagore E, et al. Mohs micrographic surgery in dermatofibrosarcoma protuberans allows tumour clearance with smaller margins and greater preservation of healthy tissue compared with conventional surgery: a study of 74 primary cases. Br J Dermatol. 2014;172:1303. An interesting article that uses computer imaging to support the tissue-sparing qualities of MMS compared to WLE.

    Article  Google Scholar 

  69. Champagne MA, Capdeville R, Krailo M, Qu W, Peng B, Rosamilia M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a children’s oncology group phase I study. Blood. 2004;104:2655–60.

    Article  CAS  PubMed  Google Scholar 

  70. Barr RD. Imatinib mesylate in children and adolescents with cancer. Pediatr Blood Cancer. 2010;55:18–25.

    PubMed  Google Scholar 

  71. Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer. 2002;100:623–6.

    Article  CAS  PubMed  Google Scholar 

  72. Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S, Conrad EU, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol. 2002;20:3586–91.

    Article  CAS  PubMed  Google Scholar 

  73. Labropoulos SC, Razis ED. Imatinib in the treatment of dermatofibrosarcoma protuberans. Biologics. 2007;1:347–53.

    PubMed Central  CAS  PubMed  Google Scholar 

  74. McArthur GA, Demetri GD, Van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 2005;23:866–73.

    Article  CAS  PubMed  Google Scholar 

  75. Kerob D, Procher R, Verola O, Dalle S, Maubec E, Aubin F, et al. Imatinib mesylate as a preoperative therapy in deratofibrosarcoma: results of a multicenter phase II study on 25 patients. Clin Cancer Res. 2010;16:3288–95.

    Article  CAS  PubMed  Google Scholar 

  76. Rutkowski P, Van GM, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010;28:1772–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  77. Rutowski P, Dębiec-Rychter M, Nowecki Z, Michej W, Symonides M, Ptaszynski K, et al. Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgery. J Eur Acad Dermatol Venereol. 2011;25:264–70.

  78. Malhotra B, Schuetze SM. Dermatofibrosarcoma protuberans treatment with platelet derived growth factor receptor inhibitor: a review of clinical trial results. Curr Opin Oncol. 2012;24:419–24. A good review of the current data behind the use of imatinib mesylate in the treatment of DFSP.

    Article  CAS  PubMed  Google Scholar 

  79. Ugurel S, Mentzel T, Utikal J, Helmbold P, Mohr P, Pföhler C, et al. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow up. Clin Cancer Res. 2013;20:499–510. An novel article that looks at the neoadjuvant use of imatinib mesylate in the treatment of DFSP.

  80. Gooskens SL, Oranje AP, van Adrichem LN, de Waard-van der Spek FB, den Hollander JC, van de Ven CP, et al. Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP). Pediatr Blood Cancer. 2010;55:369–73.

    Article  PubMed  Google Scholar 

  81. Price VE, Fletcher JA, Zienlenska M, Cole W, Viero S, Manson DE, et al. Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans. Pediatr Blood Cancer. 2005;44:511–5.

    Article  PubMed  Google Scholar 

  82. Ahmed AA, Ostlie D, Fraser JD, Newll B, Cooley L. Dermatofibrosarcoma protuberans in the breast of a 2-year-old girl. Ann Diagn Pathol. 2010;14:279–83.

    Article  PubMed  Google Scholar 

  83. Pretel-Irazabal M, Tuneu-Valls A, Ormaechea-Pérez N. Adverse skin effects of imatinib, a tyrosine kinase inhibitor. ACTAS. 2014;105:655–61. An excellent review of the side effects of imatinib mesylate.

  84. Dagan R, Morris CG, Zlotecki RA, Scarborough MT, Mendenhall WM. Radiotherapy in the treatment of dermatofibrosarcoma protuberans. Am J Clin Oncol. 2005;28:537–9.

    Article  PubMed  Google Scholar 

  85. Sun LM, Wang CJ, Huang CC, Leung SW, Chen HC, Fang FM, et al. Dermatofibrosarcoma protuberans: treatment results of 35 cases. Radiother Oncol. 2000;57:175–81.

    Article  CAS  PubMed  Google Scholar 

  86. Williams N, Morris C, Kirwan J, et al. Radiotherapy for dermatofibrosarcoma protuberans. Am J Clin Oncol. 2014;37:430–2. A good article that looks at the use of radiotherapy in DFSP.

    Article  PubMed  Google Scholar 

  87. Huber GF, Matthews TW, Dort JC. Radiation-induced soft tissue sarcomas of the head and neck. J Otolaryngol. 2007;36:93–7.

    Article  PubMed  Google Scholar 

  88. Kamiya T, Saga K, Kaneko R, Ono I, Kawada M, Maeda Y. Postradiation dermatofibrosarcoma protuberans. Acta Derm Venereol. 2006;86:152–3.

    PubMed  Google Scholar 

  89. Shin YR, Kim JY, Sung MS, Jung JH. Sonographic findings of dermatofibrosarcoma protuberans with pathologic correlation. J Ultrasound Med. 2008;27:269–74.

    PubMed  Google Scholar 

  90. Lee SJ, Mahoney MC, Shaughnessy E. Dermatofibrosarcoma protuberans of the breast: imaging features and review of the literature. AJR Am J Roentgenol. 2009;193:W64–9.

    Article  PubMed  Google Scholar 

  91. Torreggiani WC, Al-Ismail K, Munk PL, Nicolaou S, O’Connell JX, Knowling MA. Dermatofibrosarcoma protuberans: MR imaging features. AJR Am J Roentgenol. 2002;178:989–93.

    Article  PubMed  Google Scholar 

  92. Riggs K, McGuigan KL, Morrison WB, Samie FH, Humphrey’s T. Role of magnetic resonance imaging in perioperative assessment of dermatofibrosarcoma protuberans. Dermatol Surg. 2009;35:2036–41.

    Article  CAS  PubMed  Google Scholar 

  93. Navarro OM, Laffan EE, Ngan BY. Pediatric soft-tissue tumors and pseudo tumors: MR imaging features with pathologic correlation: part 1. Imaging approach, pseudo-tumors, vascular lesions, and adipocytic tumors. Radiographics. 2009;29:887–906.

    Article  PubMed  Google Scholar 

  94. Thornton SL, Reid J, Papay FA, Vidimos AT. Childhood dermatofibrosarcoma protuberans: role of preoperative imaging. J Am Acad Dermatol. 2005;53:76–83.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Nathalie Zeitouni, Kevin Cavanaugh, and Jason DuPont declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Arizona, 1515 N. Campbell Avenue, Tucson, AZ, 85724, USA

    Nathalie Zeitouni, Kevin Cavanaugh & Jason DuPont

Authors
  1. Nathalie Zeitouni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kevin Cavanaugh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jason DuPont
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nathalie Zeitouni.

Additional information

This article is part of the Topical Collection on Skin Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zeitouni, N., Cavanaugh, K. & DuPont, J. Dermatofibrosarcoma Protuberans: an Update and Review. Curr Derm Rep 4, 195–204 (2015). https://doi.org/10.1007/s13671-015-0120-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13671-015-0120-7

Keywords

Search

Navigation